Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692732 | 0.99 | MME (0.46) | MMEITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL5598794 | 0.99 | MME (0.46) | MMEITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL5598789 | 0.99 | MME (0.46) | MMEITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL4589435 | 0.98 | MME (0.45) | MMEITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL7806530 | 0.91 | SLC15A2 (0.54) | ITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL7799086 | 0.91 | SLC15A2 (0.54) | ITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL8012953 | 0.91 | SLC15A2 (0.54) | ITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL9390320 | 0.91 | SLC15A2 (0.54) | ITGB3ITGA2BSLC15A2GNPAT | |
| SCHEMBL31453803 | 0.91 | SLC15A2 (0.49) | MMEITGB3ITGA2BSLC15A2 | |
| SCHEMBL20783813 | 0.91 | SLC15A2 (0.49) | MMEITGB3ITGA2BSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110206790-A1 | Antimicrobial Foamable Soaps | OHSO CLEAN, INC | 2011-08-25 | — | — | US | disclosed |
| EP-2350252-A2 | ANTIMICROBIAL FOAMABLE SOAPS | Ohso Clean, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010059366-A2 | ANTIMICROBIAL FOAMABLE SOAPS | OHSO CLEAN, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| EP-0765152-B1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORP (US) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | MME 2453/4885ITGB3 4478/4885ITGA2B 4335/4885 |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | MME 686/4885ITGB3 4140/4885ITGA2B 4545/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | MME 1051/4885ITGB3 3811/4885ITGA2B 4303/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | MME 2077/4885ITGB3 4719/4885ITGA2B 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.